AR and prostate carcinoma: Using a panel of normal and cancer cell lines from 14 distinct lineages, we found AR and FOXA1-driven prostate cancer cells to be preferentially sensitive to AU-15330 (half-maximal inhibitory concentrations (IC50) < 100 nM; Fig. 1c, Extended Data Fig. 1f, g, Supplementary Table 1).